Results 11 to 20 of about 12,776,407 (326)
Patient Preference and Adherence, 2014 Siwan Seaman,1 Annmarie Nelson,2 Simon Noble2 1Department of Palliative Medicine, Royal Gwent Hospital, Newport, Wales, UK; 2Marie Curie Palliative Care Research Unit, Cardiff University, Cardiff, Wales, UK Background: Venous thromboembolism is a common
Seaman S, Nelson A, Noble S
doaj +2 more sources
The anti-factor Xa range for low molecular weight heparin thromboprophylaxis
Hematology Reports, 2015 Low molecular weight heparins (LMWHs) are now the mainstay option in the prevention and treatment of venous thromboembolism. In some patients receiving therapeutic doses of LMWH, activity can be measured by quantifying the presence of Anti-factor Xa ...
Matthew Y. Wei, Salena M. Ward
doaj +2 more sources
Lipolysis generates platelet dysfunction after in vivo heparin administration [PDF]
, 2002 Heparin, when administered to patients undergoing operations using cardiopulmonary bypass, induces plasma changes that gradually impair platelet macroaggregation, but heparinization of whole blood in vitro does not have this effect.
Day, S. +3 more
core +8 more sources
Update on the clinical use of the low-molecular-weight heparin, parnaparin
Vascular Health and Risk Management, 2009 Giuseppe Camporese1, Enrico Bernardi2, Franco Noventa31Unit of Angiology and 3Department of Clinical and Experimental Medicine, Clinical Epidemiology Group, University Hospital of Padua, Italy; 2Department of Emergency and Accident Medicine, Hospital of ...
Giuseppe Camporese +2 more
doaj +1 more source
The potential for circular dichroism as an additional facile and sensitive method of monitoring low-molecular-weight heparins and heparinoids [PDF]
, 2009 The ultraviolet circular dichroism (CD) spectra of commercial low-molecular-weight heparins, heparinoids and other anticoagulant preparations have been recorded between 180 and 260 nm.
Fernig, David G. +7 more
core +4 more sources
Inhibition of trypsin by heparin and dalteparin, a low molecular weight heparin [PDF]
Journal of the Serbian Chemical Society, 2009 The interaction between trypsin, a prototype S1 serine protease, with heparin and its low molecular weight derivative dalteparin were investigated. Direct inhibition of the proteolytic activity of trypsin by heparin and dalteparin, used in concentrations
OLIVERA M. BOSNIĆ +3 more
doaj +3 more sources
LOW-MOLECULAR-WEIGHT HEPARINS [PDF]
Hematology/Oncology Clinics of North America, 1998 Low-molecular-weight heparins (LMWH) are a new group of parenteral anticoagulants. They represent a major clinical advance in anticoagulation since the identification of unfractionated heparin (UFH) in 1922 and the introduction of the synthetic coumarin derivative, warfarin, in 1948.
J N, Huang, A, Shimamura
openaire +4 more sources
Journal of the American Medical Association (JAMA), 2023 Importance In patients with cancer who have venous thromboembolism (VTE) events, long-term anticoagulation with low-molecular-weight heparin (LMWH) is recommended to prevent recurrent VTE.
D. Schrag +15 more
semanticscholar +1 more source
Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture.
New England Journal of Medicine, 2023 BACKGROUND Clinical guidelines recommend low-molecular-weight heparin for thromboprophylaxis in patients with fractures, but trials of its effectiveness as compared with aspirin are lacking.
R. O'Toole +16 more
semanticscholar +1 more source
American Heart Journal Plus, 2023 Unfractionated heparin (UFH) is commonly used for several life-threatening conditions requiring anticoagulant therapy but failure to reach therapeutic levels in 24 h can be associated with adverse outcomes.
Kayla Torppey +7 more
doaj +1 more source